IP25: Prostate Cancer: Detection & Screening II
Saturday, May 16, 2026 7:00 AM to 9:00 AM · 2 hr. (America/New_York)
145AB
Poster and Podium Sessions
Oncology: Prostate
Saturday, May 16
IP25-01: Intercenter variability in the accuracy of risk calculators based on MRI parameters: Extensive external validation of 7 contemporary risk calculators
Saturday, May 16, 2026 7:00 AM to 9:00 AM
145AB
IP25-02: Circulating Tumor DNA (ctDNA) as a Prognostic Biomarker: A Meta-analysis of Androgen Receptor Gene Alterations in Metastatic Castration-Resistant Prostate Cancer.
Saturday, May 16, 2026 7:00 AM to 9:00 AM
145AB
Mingrui Huang
IP25-03: Outcomes in Men with Palpable Prostate Cancer with Normal Range Prostate Specific Antigen
Saturday, May 16, 2026 7:00 AM to 9:00 AM
145AB
IP25-04: Automated Gleason Pattern Segmentation in Prostate Whole Slide Digitized Pathology Using Foundation Model Feature Embeddings
Saturday, May 16, 2026 7:00 AM to 9:00 AM
145AB
Aakriti Shah
IP25-05: Organ-Specific Family Cancer History and Prostate Cancer Risk in the Biomarkers of Prostate Cancer Prevention and Environment (BIOCaPPE) Multicenter Observational Prospective Study
Saturday, May 16, 2026 7:00 AM to 9:00 AM
145AB
IP25-06: Complementary Diagnostic Value of Micro-Ultrasound in Equivocal Prostate MRI: An Updated Retrospective Analysis from a Tertiary Referral Center
Saturday, May 16, 2026 7:00 AM to 9:00 AM
145AB
IP25-07: Clinical and sociodemographic factors associated with continued Prostate cancer screening after age 70
Saturday, May 16, 2026 7:00 AM to 9:00 AM
145AB
IP25-10: Elevated Prostate Specific Antigen due to Indwelling Urethral Catheterization: Myth or Fact? A Systematic Review and Meta-Analysis
Saturday, May 16, 2026 7:00 AM to 9:00 AM
145AB
IP25-11: Optimizing Pathways for Prostate Cancer Detection: Comparative Performance of mpMRI, 4Kscore, and ExoDx in a Prospective Cohort
Saturday, May 16, 2026 7:00 AM to 9:00 AM
145AB
IP25-12: PROSTATE CANCER SCREENING DISPARITIES: A COSMIC INSIGHT
Saturday, May 16, 2026 7:00 AM to 9:00 AM
145AB
IP25-13: Downgrading from Prostate Biopsy to Radical Prostatectomy: Incidence and Predictive Factors from a Large Contemporary Cohort
Saturday, May 16, 2026 7:00 AM to 9:00 AM
145AB
IP25-14: External Validation of the PRI-MUS Scoring System: A Secondary Analysis of the OPTIMUM Randomized Controlled Trial
Saturday, May 16, 2026 7:00 AM to 9:00 AM
145AB
IP25-15: Too Old for Prostate Biopsy?
Saturday, May 16, 2026 7:00 AM to 9:00 AM
145AB
IP25-16: Does periprostatic lidocaine block add value during sedated prostate biopsy? A randomized prospective trial
Saturday, May 16, 2026 7:00 AM to 9:00 AM
145AB
IP25-17: Can mpMRI and PSMA PET Predict Contralateral Clinically Significant Prostate Cancer at Biopsy and Radical Prostatectomy? Implications for Focal Therapy Candidate Selection
Saturday, May 16, 2026 7:00 AM to 9:00 AM
145AB
IP25-18: Prostate Cancer Screening Patterns Between Internal Medicine and Family Medicine-Trained Primary Care Physicians: A Retrospective Cohort Study
Saturday, May 16, 2026 7:00 AM to 9:00 AM
145AB
IP25-19: Concomitant MRI-detected and MRI-undetected prostate cancer with implications for biopsy strategies and focal therapy planning: An analysis of the PROMIS and PICTURE trials
Saturday, May 16, 2026 7:00 AM to 9:00 AM
145AB
IP25-20: Fully hybrid 18F-PSMA PET/MRI as a One-Stop Approach for the Diagnosis of Clinically-Significant Prostate Cancer: Preplanned Interim Results from a Phase II Prospective Trial
Saturday, May 16, 2026 7:00 AM to 9:00 AM
145AB
IP25-21: Exploring the Diagnostic Yield of Prostate MRI for Prostate Cancer Detection in Younger Men: Implications for MRI interpretation across Different Age Thresholds
Saturday, May 16, 2026 7:00 AM to 9:00 AM
145AB
IP25-22: The Influence of Lesion Volume and Urologist Experience on the Added Value of Perilesional Biopsy for Detecting Clinically Significant Prostate Cancer
Saturday, May 16, 2026 7:00 AM to 9:00 AM
145AB
IP25-23: Risk of missing clinically significant prostate cancer with omission of systematic biopsies: results from a large institutional series
Saturday, May 16, 2026 7:00 AM to 9:00 AM
145AB
IP25-24: The impact of Race on oncological outcomes in patients with an initial negative prostate biopsy: results from a contemporary North America cohort
Saturday, May 16, 2026 7:00 AM to 9:00 AM
145AB
IP25-25: Is the digital rectal exam (DRE) still relevant in the era of MRI imaging? Results of an international multi-institutional study
Saturday, May 16, 2026 7:00 AM to 9:00 AM
145AB
IP25-26: On-site Real-time Evaluation of Target Prostate Biopsy with Confocal Laser Microscopy
Saturday, May 16, 2026 7:00 AM to 9:00 AM
145AB
IP25-27: The Comparison of Microultrasound-Guided and Multiparametric MRI-Targeted Prostate Biopsy: A Systematic Review and Meta-Analysis
Saturday, May 16, 2026 7:00 AM to 9:00 AM
145AB
IP25-28: Predictive capability of combining ExoDx (EPI) and pre-biopsy prostate MRI in detecting clinically significant prostate cancer in African American men.
Saturday, May 16, 2026 7:00 AM to 9:00 AM
145AB
IP25-29: Micro-Ultrasound vs Multiparametric MRI in Prostate Cancer Detection: Real-World Cohort Analysis of 262 Biopsies
Saturday, May 16, 2026 7:00 AM to 9:00 AM
145AB
